Are biotech company valuations warranted?
Sam Isaly, managing partner of OrbiMed Investors and portfolio manager of the Worldwide Healthcare trust, says strategically-driven M&A activity and leaps in scientific research are continuing to drive growth for the sector
Driven by secular tailwinds and advances in scientific research, the MSCI World Healthcare index has returned 10.74% on an annualised basis over the past ten years. In 2013 and 2014 alone the index returned...
More on Investment
Back to Top
